PROGEN Prostatype Genomics AB (publ)
Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests. The company offers a Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, RTqPCR kit, patient database and algorithms, Prostatype Web System (PWS), and tumor stage, as well as calculates the P-score. Its test is based on a database containing prostate cancer patients; and provides decision support for patients and doctors when making a treatment decision. The company was incorporated in 2007 and is headquartered in Nacka, Sweden.…
Industry Peers
Diagnostics & ResearchKey Statistics
About Prostatype Genomics (STO: PROGEN)
›
Prostatype Genomics (STO: PROGEN) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 7 employees.
The shares were at 0.0926 SEK on 19 November 2026, down 83.5% over 52 weeks. Its 52-week range is 0.0702 SEK to 2.280 SEK: the price is 95.9% below the high and 31.9% above the low.
Its market capitalisation is 14.41M SEK.
Prostatype Genomics reports return on equity of -167.7% and revenue up 85.8% year over year.
It holds more cash than debt, a net cash position of 392.00K SEK. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.